Document:

Exhibit
10.52

 

SECURITIES
PURCHASE AGREEMENT

 

This
SECURITIES PURCHASE AGREEMENT, dated as of May 27, 2020 (the “Agreement”), by and between The Greater
Cannabis Company Inc., a Florida corporation with headquarters located at 15 Walter Avenue, Suite 101, Baltimore, MD 21208
(the “Company”), and GW Holdings Group, LLC, a New York limited liability company with its address at
137 Montague Street, Suite 291, Brooklyn, NY 11201 (the “Investor”).

 

WHEREAS:

 

A.
The Company and the Investor are executing and delivering this Agreement in reliance upon the exemption from securities registration
afforded by the rules and regulations as promulgated by the United States Securities and Exchange Commission (the “SEC”)
under the Securities Act of 1933, as amended (the “Securities Act”);

 

B.
Investor desires to purchase and the Company desires to issue and sell, upon the terms and conditions set forth in this Agreement,
a 6% convertible promissory note of the Company, in the form attached hereto as Exhibit A, in the aggregate principal
amount of Forty Thousand Five Hundred, U.S. Dollars and Zero Cents ($40,500.00) (the “Principal Amount”) due
and payable on May 27, 2021, together with any note(s) issued in replacement thereof or as a dividend thereon or otherwise with
respect thereto in accordance with the terms thereof (the “Note”) which shall contain a Three Thousand U.S.
Dollars and Zero Cents ($3,000.00) Original Issue Discount (“OID”) such that the purchase price of the Note
shall be Thirty-Seven Thousand Five Hundred U.S. Dollars and Zero Cents ($37,500.00) (the “Purchase Price”),
convertible into shares of common stock, $0.001 par value per share, of the Company (the “Common Stock”), upon
the terms and subject to the limitations and conditions set forth in such Note; and

 

C.
The Investor wishes to purchase, upon the terms and conditions stated in this Agreement, the Note.

 

NOW
THEREFORE, the Company and the Investor severally (and not jointly) hereby agree as follows:

 

1.
Purchase and Sale of Note.

 

2.
Purchase of Note. On the Closing Date (as defined below), the Company shall issue and sell to the Investor and the Investor
agrees to purchase from the Company the Note

 

Company Initials: _____

 

    	 

     

    

 

a.
Form of Payment. On the Closing Date (as defined below), the Investor shall pay the Purchase Price for the Note to be issued
and sold to it at the Closing (as defined below) by wire transfer of immediately available funds to the Company, in accordance
with the Company’s written wiring instructions, against delivery of the Note in the Principal Amount, and the Company shall
deliver such duly executed Note on behalf of the Company, to the Investor, against delivery of such Purchase Price.

 

b.
Closing Date. The date and time of the first issuance and sale of the Note pursuant to this Agreement (the “Closing
Date”) shall be on or about May 27, 2020, or such other mutually agreed upon time. The closing of the transactions contemplated
by this Agreement (the “Closing”) shall occur on the Closing Date at such location as may be agreed to by the
parties.

 

3.
Investor’s Representations and Warranties. The Investor represents and warrants to the Company that:

 

a.
Investment Purpose. As of the date hereof, the Investor is purchasing the Note and the shares of Common Stock issuable
upon conversion of or otherwise pursuant to the Note (such shares of Common Stock being collectively referred to herein as the
“Conversion Shares” and, collectively with the Note, the “Securities”) for its own account
and not with a present view towards the public sale or distribution thereof, except pursuant to sales registered or exempted from
registration under the Securities Act; provided, however, that by making the representations herein, the Investor
does not agree to hold any of the Securities for any minimum or other specific term and reserves the right to dispose of the Securities
at any time in accordance with or pursuant to a registration statement or an exemption under the Securities Act.

 

b.
Accredited Investor Status. The Investor is an “accredited investor” as that term is defined under the Securities
Act (an “Accredited Investor”).

 

c.
Reliance on Exemptions. The Investor understands that the Securities are being offered and sold to it in reliance upon
specific exemptions from the registration requirements of United States federal and state securities laws and that the Company
is relying upon the truth and accuracy of, and the Investor’s compliance with, the representations, warranties, agreements,
acknowledgments and understandings of the Investor set forth herein in order to determine the availability of such exemptions
and the eligibility of the Investor to acquire the Securities.

 

    	2

     

    

 

d.
Information. The Investor and its advisors, if any, have been, and for so long as the Note remain outstanding will, subject
to applicable law and regulation, continue to be, furnished with all materials relating to the business, finances and operations
of the Company and materials relating to the offer and sale of the Securities which have been requested by the Investor or its
advisors. The Investor and its advisors, if any, have been, and for so long as the Note remain outstanding will continue to be,
afforded the opportunity to ask questions of the Company. Notwithstanding the foregoing, the Company has not disclosed to the
Investor any material nonpublic information and will not disclose such information unless such information is disclosed to the
public prior to or promptly following such disclosure to the Investor. Neither such inquiries nor any other due diligence investigation
conducted by Investor or any of its advisors or representatives shall modify, amend or affect Investor’s right to rely on
the Company’s representations and warranties contained in Section 3 below. The Investor understands that its investment
in the Securities involves a significant degree of risk. The Investor is not aware of any facts that may constitute a breach of
any of the Company’s representations and warranties made herein.

 

e.
Governmental Review. The Investor understands that neither the SEC nor any state securities agency or any other government
or governmental agency has passed upon or made any recommendation or endorsement of the Securities.

 

f.
Transfer or Re-sale. The Investor understands that the sale or re-sale of the Securities has not been and is not being
registered under the Securities Act or any applicable state securities laws, and the Securities may not be transferred unless
the Securities are sold pursuant to an effective registration statement under the Securities Act, the Investor shall have delivered
to the Company, at the cost of the Investor, an opinion of counsel that shall be in form, substance and scope customary for opinions
of counsel in comparable transactions to the effect that the Securities to be sold or transferred may be sold or transferred pursuant
to an exemption from such registration, which opinion shall be accepted by the Company, the Securities are sold or transferred
to an “affiliate” (as defined in Rule 144 promulgated under the Securities Act (or a successor rule) (“Rule
144”)) of the Investor who agrees to sell or otherwise transfer the Securities only in accordance with this Section
2(f) and who is an Accredited Investor, the Securities are sold pursuant to Rule 144 or other available exemption from the registration
requirements of the Securities Act, or the Securities are sold pursuant to Regulation S under the Securities Act (or a successor
rule) (“Regulation S”), and the Investor shall have delivered to the Company, at the cost of the Investor,
an opinion of counsel that shall be in form, substance and scope customary for opinions of counsel in corporate transactions,
which opinion shall be accepted by the Company; (ii) any sale of such Securities made in reliance on Rule 144 may be made only
in accordance with the terms of said Rule and further, if said Rule is not applicable, any re-sale of such Securities under circumstances
in which the seller (or the person through whom the sale is made) may be deemed to be an “underwriter” (as that term
is defined by Section 2(a)(11) of the Securities Act) may require compliance with some other exemption under the Securities Act
or the rules and regulations of the SEC thereunder; and (iii) neither the Company nor any other person is under any obligation
to register such Securities under the Securities Act or any state securities laws or to comply with the terms and conditions of
any exemption thereunder (in each case). Notwithstanding the foregoing or anything else contained herein to the contrary, the
Securities may be pledged as collateral in connection with a bona fide margin account or other lending arrangement.

 

    	3

     

    

 

g.
Legends. The Investor understands that the Note and, until such time as the Conversion Shares have been registered under
the Securities Act or may be sold pursuant to Rule 144 or Regulation S without any restriction as to the number of securities
as of a particular date that can then be immediately sold, the Conversion Shares shall bear a restrictive legend in substantially
the following form (and a stop-transfer order may be placed against transfer of the certificates for such Securities):

 

“NEITHER
THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE
HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT
BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER), IN
A GENERALLY ACCEPTABLE FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144 OR RULE
144A UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT
OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.”

 

The
legend set forth above shall be removed and the Company shall direct its transfer agent to issue a certificate without such legend
to the holder of any Security upon which it is stamped, if, unless otherwise required by applicable state securities laws, (a)
such Security is registered for resale under an effective registration statement filed under the Securities Act or otherwise may
be sold pursuant to Rule 144 or Regulation S without any restriction as to the number of securities as of a particular date that
can then be immediately sold and (b) such holder provides the Company with an opinion of counsel, in form, substance and scope
customary for opinions of counsel in comparable transactions, to the effect that a public resale or transfer of such Security
may be made without registration under the Securities Act, which opinion shall be accepted by the Company so that the sale or
transfer is effected. The Investor agrees to sell all Securities, including those represented by a certificate(s) from which the
legend has been removed, in compliance with applicable prospectus delivery requirements, if any. In the event that the Company
does not accept the opinion of counsel provided by the Investor with respect to the transfer of Securities pursuant to an exemption
from registration, such as Rule 144 or Regulation S, within 2 business days, it will be considered an Event of Default under the
Note. Notwithstanding the foregoing, the Investor acknowledges and agrees that it will be required to agree any opinion of counsel
with the Company’s transfer agent and that so long as the Company does not instruct the transfer agent not to accept the
opinion of counsel, the Company shall not be responsible or liable for any delays caused by the transfer agent.

 

    	4

     

    

 

h.
Authorization; Enforcement. This Agreement has been duly and validly authorized. This Agreement has been duly executed
and delivered on behalf of the Investor, and this Agreement constitutes a valid and binding agreement of the Investor enforceable
in accordance with its terms.

 

i.
Residency. The Investor is a resident of or domiciled in the jurisdiction set forth immediately below the Investor’s
name on the signature pages hereto.

 

4.
Representations and Warranties of the Company. The Company represents and warrants to the Investor that:

 

a.
Organization and Qualification. The Company and each of its subsidiaries, if any, is a corporation duly organized, validly
existing and in good standing under the laws of the jurisdiction in which it is incorporated, with full power and authority (corporate
and other) to own, lease, use and operate its properties and to carry on its business as and where now owned, leased, used, operated
and conducted.

 

b.
Authorization; Enforcement. (i) The Company has all requisite corporate power and authority to enter into and perform this
Agreement, the Note and to consummate the transactions contemplated hereby and thereby and to issue the Securities, in accordance
with the terms hereof and thereof, (ii) the execution and delivery of this Agreement, the Note by the Company and the consummation
by it of the transactions contemplated hereby and thereby (including without limitation, the issuance of the Note and the issuance
and reservation for issuance of the Conversion Shares issuable upon conversion or exercise thereof) and the performance of its
obligations thereunder have been duly authorized by the Company’s Board of Directors and no further consent or authorization
of the Company, its Board of Directors, or its shareholders is required, (iii) this Agreement has been duly executed and delivered
by the Company by its authorized representative, and such authorized representative is the true and official representative with
authority to sign this Agreement and the other documents executed in connection herewith and bind the Company accordingly, and
(iv) this Agreement constitutes, and upon execution and delivery by the Company of the Note, each of such instruments will constitute,
a legal, valid and binding obligation of the Company enforceable against the Company in accordance with its terms.

 

c.
Issuance of Shares. The Conversion Shares are duly authorized and reserved for issuance and, upon conversion of the Note
in accordance with its respective terms, will be validly issued, fully paid and non-assessable, and free from all taxes, liens,
claims and encumbrances with respect to the issue thereof and shall not be subject to preemptive rights or other similar rights
of shareholders of the Company and will not impose personal liability upon the holder thereof.

 

d.
Acknowledgment of Dilution. The Company understands and acknowledges the potentially dilutive effect to the outstanding
Common Stock upon the issuance of the Conversion Shares upon conversion of the Note. The Company further acknowledges that its
obligation to issue Conversion Shares upon conversion of the Note in accordance with this Agreement, the Note is absolute and
unconditional regardless of the dilutive effect that such issuance may have on the ownership interests of other shareholders of
the Company.

 

    	5

     

    

 

e.
No Conflicts. The execution, delivery and performance of this Agreement, the Note by the Company and the consummation by
the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance and reservation for
issuance of the Conversion Shares) will not (i) conflict with or result in a violation of any provision of the Certificate of
Incorporation or By-laws, or (ii) violate or conflict with, or result in a breach of any provision of, or constitute a default
(or an event which with notice or lapse of time or both could become a default) under, or give to others any rights of termination,
amendment, acceleration or cancellation of, any agreement, indenture, patent, patent license or instrument to which the Company
or any of its subsidiaries is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree
(including federal and state securities laws and regulations and regulations of any self-regulatory organizations to which the
Company or its securities are subject) applicable to the Company or any of its subsidiaries or by which any property or asset
of the Company or any of its subsidiaries is bound or affected (except for such conflicts, defaults, terminations, amendments,
accelerations, cancellations and violations as would not, individually or in the aggregate, have a material adverse effect). All
consents, authorizations, orders, filings and registrations which the Company is required to obtain pursuant to the preceding
sentence have been obtained or effected on or prior to the date hereof. The Company is not in violation of the listing requirements
of the Over-the-Counter Quotations Bureau (the “OTCQB”) and does not reasonably anticipate that the Common
Stock will be delisted by the OTCQB in the foreseeable future, nor are the Company’s securities “chilled” by
DTC. The Company and its subsidiaries are unaware of any facts or circumstances, which might give rise to any of the foregoing.

 

f.
Absence of Litigation. Except as disclosed in the Company’s public filings, there is no action, suit, claim, proceeding,
inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending
or, to the knowledge of the Company or any of its subsidiaries, threatened against or affecting the Company or any of its subsidiaries,
or their officers or directors in their capacity as such, that could have a material adverse effect. Schedule 3(f) contains a
complete list and summary description of any pending or, to the knowledge of the Company, threatened proceeding against or affecting
the Company or any of its subsidiaries, without regard to whether it would have a material adverse effect. The Company and its
subsidiaries are unaware of any facts or circumstances, which might give rise to any of the foregoing. As used herein, “knowledge”
or any other similar knowledge qualification, means the actual or constructive knowledge of any director or officer of the Company,
after due inquiry.

 

    	6

     

    

 

g.
Acknowledgment Regarding Investor’ Purchase of Securities. The Company acknowledges and agrees that the Investor
is acting solely in the capacity of arm’s length purchasers with respect to this Agreement and the transactions contemplated
hereby. The Company further acknowledges that the Investor is not acting as a financial advisor or fiduciary of the Company (or
in any similar capacity) with respect to this Agreement and the transactions contemplated hereby and any statement made by the
Investor or any of its respective representatives or agents in connection with this Agreement and the transactions contemplated
hereby is not advice or a recommendation and is merely incidental to the Investor’ purchase of the Securities. The Company
further represents to the Investor that the Company’s decision to enter into this Agreement has been based solely on the
independent evaluation of the Company and its representatives.

 

h.
No Integrated Offering. Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf, has
directly or indirectly made any offers or sales in any security or solicited any offers to buy any security under circumstances
that would require registration under the Securities Act of the issuance of the Securities to the Investor. The issuance of the
Securities to the Investor will not be integrated with any other issuance of the Company’s securities (past, current or
future) for purposes of any shareholder approval provisions applicable to the Company or its securities.

 

i.
Title to Property. Except as disclosed in the Company’s public filings, the Company and its subsidiaries have good
and marketable title in fee simple to all real property and good and marketable title to all personal property owned by them which
is material to the business of the Company and its subsidiaries, in each case free and clear of all liens, encumbrances and defects
except such as are described in Schedule 3(i) or such as would not have a material adverse effect. Any real property and facilities
held under lease by the Company and its subsidiaries are held by them under valid, subsisting and enforceable leases with such
exceptions as would not have a material adverse effect.

 

j.
Bad Actor. None of the Company, or any its predecessors or any affiliate issuer, any director, executive officer or other
officer of the Company, any beneficial owner (as that term is defined in Rule 13d-3 under the Exchange Act) of 20% or more of
the Company’s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term
is defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the time of sale of any securities
(each, an “Covered Person” and, collectively, “Covered Persons”) is subject to any of the
“Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a “Disqualification
Event”), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3) under the Securities Act. The Company
has exercised reasonable care to determine (i) the identity of each person that is a Covered Person; and (ii) whether any Covered
Person is subject to a Disqualification Event.

 

k.
Breach of Representations and Warranties by the Company. If the Company breaches any of the representations or warranties
set forth in this Section 3, and in addition to any other remedies available to the Investor pursuant to this Agreement, it will
be considered an Event of default under the Note.

 

    	7

     

    

 

5.
Covenants.

 

a.
Expenses. At the Closing, the Company shall reimburse Investor for expenses incurred by them in connection with the negotiation,
preparation, execution, delivery and performance of this Agreement and the other agreements to be executed in connection herewith
(“Documents”), including, without limitation, reasonable attorneys’ and consultants’ fees and expenses,
transfer agent fees, fees for stock quotation services, fees relating to any amendments or modifications of the Documents or any
consents or waivers of provisions in the Documents, fees for the preparation of opinions of counsel, escrow fees, and costs of
restructuring the transactions contemplated by the Documents. When possible, the Company must pay these fees directly, otherwise
the Company must make immediate payment for reimbursement to the Investor for all fees and expenses immediately upon written notice
by the Investor or the submission of an invoice by the Investor. The Company’s obligation with respect to this transaction
is to reimburse Investor’s expenses shall be $2,000 in legal fees, which shall be deducted from the Note when funded.

 

b.
Listing. The Company shall promptly secure the listing of the Conversion Shares upon each national securities exchange
or automated quotation system, if any, upon which shares of Common Stock are then listed (subject to official notice of issuance)
and, so long as the Investor owns any of the Securities, shall maintain, so long as any other shares of Common Stock shall be
so listed, such listing of all Conversion Shares from time to time issuable upon conversion of the Note. The Company will obtain
and, so long as the Investor owns any of the Securities, maintain the listing and trading of its Common Stock on the OTCQB or
any equivalent replacement exchange, the Nasdaq National Market (“Nasdaq”), the Nasdaq SmallCap Market (“Nasdaq
SmallCap”), the New York Stock Exchange (“NYSE”), or the American Stock Exchange (“AMEX”)
and will comply in all respects with the Company’s reporting, filing and other obligations under the bylaws or rules of
the Financial Industry Regulatory Authority (“FINRA”) and such exchanges, as applicable. The Company shall
promptly provide to the Investor copies of any notices it receives from the OTCQB and any other exchanges or quotation systems
on which the Common Stock is then listed regarding the continued eligibility of the Common Stock for listing on such exchanges
and quotation systems.

 

c.
Corporate Existence. So long as the Investor beneficially owns any Note, the Company shall maintain its corporate existence
and shall not sell all or substantially all of the Company’s assets, except in the event of a merger or consolidation or
sale of all or substantially all of the Company’s assets, where the surviving or successor entity in such transaction (i)
assumes the Company’s obligations hereunder and under the agreements and instruments entered into in connection herewith
and (ii) is a publicly traded corporation whose Common Stock is listed for trading on the OTCQB, Nasdaq, Nasdaq SmallCap, NYSE
or AMEX.

 

d.
No Integration. The Company shall not make any offers or sales of any security (other than the Securities) under circumstances
that would require registration of the Securities being offered or sold hereunder under the Securities Act or cause the offering
of the Securities to be integrated with any other offering of securities by the Company for the purpose of any stockholder approval
provision applicable to the Company or its securities.

 

    	8

     

    

 

e.
Registration Rights. The Company shall file a registration statement on Form S-1 (333-235938) filed with the SEC as soon
as reasonably possible to include and register an aggregate 15 million (15,000,000) shares of Common Stock issuable upon the conversion
of the Note by the Investor.

 

f.
Breach of Covenants. If the Company breaches any of the covenants set forth in this Section 4, and in addition to any other
remedies available to the Investor pursuant to this Agreement, it will be considered an event of default under the Note.

 

6.
Governing Law; Miscellaneous.

 

a.
Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York without
regard to principles of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated
by this Agreement shall be brought only in the state courts of New York or in the federal courts located in the state and county
of New York. The parties to this Agreement hereby irrevocably waive any objection to jurisdiction and venue of any action instituted
hereunder and shall not assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens. The
Company and Investor waive trial by jury. The prevailing party shall be entitled to recover from the other party its reasonable
attorney’s fees and costs. In the event that any provision of this Agreement or any other agreement delivered in connection
herewith is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative
to the extent that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such
provision, which may prove invalid or unenforceable under any law, shall not affect the validity or enforceability of any other
provision of any agreement. Each party hereby irrevocably waives personal service of process and consents to process being served
in any suit, action or proceeding in connection with this Agreement or any other Transaction Document by mailing a copy thereof
via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for
notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted
by law.

 

b.
Counterparts; Signatures by Facsimile. This Agreement may be executed in one or more counterparts, each of which shall
be deemed an original but all of which shall constitute one and the same agreement and shall become effective when counterparts
have been signed by each party and delivered to the other party. This Agreement, once executed by a party, may be delivered to
the other party hereto by facsimile transmission of a copy of this Agreement bearing the signature of the party so delivering
this Agreement.

 

    	9

     

    

 

c.
Headings. The headings of this Agreement are for convenience of reference only and shall not form part of, or affect the
interpretation of, this Agreement.

 

d.
Severability. In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute
or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed
modified to conform with such statute or rule of law. Any provision hereof which may prove invalid or unenforceable under any
law shall not affect the validity or enforceability of any other provision hereof.

 

e.
Entire Agreement; Amendments. This Agreement and the instruments referenced herein contain the entire understanding of
the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither
the Company nor the Investor makes any representation, warranty, covenant or undertaking with respect to such matters. No provision
of this Agreement may be waived or amended other than by an instrument in writing signed by the majority in interest of the Investor.

 

f.
Notices. All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder
shall be in writing and, unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered
or certified, return receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid,
or (iv) transmitted by hand delivery, telegram, or facsimile, addressed as set forth below or to such other address as such party
shall have specified most recently by written notice. Any notice or other communication required or permitted to be given hereunder
shall be deemed effective (a) upon hand delivery or delivery by facsimile, with accurate confirmation generated by the transmitting
facsimile machine, at the address or number designated below (if delivered on a business day during normal business hours where
such notice is to be received), or the first business day following such delivery (if delivered other than on a business day during
normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by
express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first
occur. The addresses for such communications shall be:

 

If
to the Company, to:

 

The
Greater Cannabis Company, Inc.

15
Walter Avenue, Suite 101

Baltimore,
MD 21208

Attn:
Aitan Zacharin, CEO

 

    	10

     

    

 

If
to the Investor:

 

GW
Holdings Group, LLC

137
Montague Street, Suite 291

Brooklyn,
NY 11201

Attn:
Noah Weinstein, Manager

 

Each
party shall provide notice to the other party of any change in address.

 

g.
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors
and assigns. Neither the Company nor the Investor shall assign this Agreement or any rights or obligations hereunder without the
prior written consent of the other. Notwithstanding the foregoing, the Investor may assign its rights hereunder to any person
that purchases Securities in a private transaction from the Investor or to any of its “affiliates,” as that term is
defined under the 1934 Act, without the consent of the Company.

 

h.
Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted
successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

 

i.
Survival. The representations and warranties of the Company and the agreements and covenants set forth in this Agreement
shall survive the closing hereunder notwithstanding any due diligence investigation conducted by or on behalf of the Investor.
The Company agrees to indemnify and hold harmless the Investor and all their officers, directors, employees and agents for direct
loss or damage arising as a direct result of or directly related to any breach or alleged breach by the Company of any of its
representations, warranties and covenants set forth in this Agreement or any of its covenants and obligations under this Agreement,
in each case, as proven in a final, non-appealable decision of a court of competent jurisdiction.

 

j.
Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things,
and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably
request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions
contemplated hereby.

 

k.
No Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to
express their mutual intent, and no rules of strict construction will be applied against any party.

 

l.
Remedies. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the
Investor by vitiating the intent and purpose of the transaction contemplated hereby. Accordingly, the Company acknowledges that
the remedy at law for a breach of its obligations under this Agreement will be inadequate and agrees, in the event of a breach
or threatened breach by the Company of the provisions of this Agreement, that the Investor shall be entitled, in addition to all
other available remedies at law or in equity, and in addition to the penalties assessable herein, to an injunction or injunctions
restraining, preventing or curing any breach of this Agreement and to enforce specifically the terms and provisions hereof, without
the necessity of showing economic loss and without any bond or other security being required.

 

[SIGNATURE
PAGE FOLLOWS]

 

    	11

     

    

 

IN
WITNESS WHEREOF, the undersigned Investor and the Company have caused this Agreement to be duly executed as of the date first
above written.

 

 

	Company:	THE
    GREATER CANNABIS COMPANY, INC.
	 	 
	 	By:	/s/
    Aitan Zacharin
	 	Name:	Aitan
    Zacharin
	 	Title:	Chief
    Executive Officer
	 	 	 
	Investor:	GW
    HOLDINGS GROUP, LLC
	 	 
	 	By:	/s/
    Noah Weinstein
	 	Name:	Noah
    Weinstein
	 	Title:	Manager

 

    	12

     

    

 

EXHIBIT
A

 

[$40,500
6% Convertible Promissory Note, less $3,000 OID]

 

    	13Exhibit 10.1

      AMENDMENT TO THE AMENDED AND RESTATED ALTERNATIVE INVESTMENT SELLING AGENT AGREEMENT

      This amendment (“Amendment”) dated as the 23rd day of June, 2020 to the Amended and Restated Alternative Investment Selling Agent Agreement (the “Agreement”) dated
        as of March 3, 2016, as amended from time to time, by and among each of the limited partnerships listed on Schedule 1 hereto (each, a “Partnership,” and together, the “Partnerships”), Ceres Managed Futures LLC, a Delaware limited liability company
        (the “General Partner”), and Morgan Stanley Smith Barney LLC, a Delaware limited liability company, currently doing business as Morgan Stanley Wealth Management (“MSSB” or “Placement Agent”). Capitalized terms used herein but not otherwise defined
        shall have the respective meanings assigned to them in the Agreement.

      W I T N E S S E T H:

      WHEREAS, the General Partner, the Partnerships and the Placement Agent agree to amend the Agreement to (i) reflect a reduction in the
        annual Ongoing Selling Agent Fee payable to the Placement Agent with respect to Class A Units of each Partnership (with the exception of Ceres Orion L.P. (“Orion”)) from 2.00% to 1.00% of the adjusted net assets of the Class A Units, (ii) reflect a
        change in the Ongoing Selling Agent Fee payable to the Placement Agent with respect to Class A Units of Orion from a transaction-based calculation to a flat annual fee of 1.00% of the adjusted net assets of Class A Units and (iii) update and
        replace Schedules 1 and 2; and

      WHEREAS, pursuant to Section 15(c) of the Agreement, any change to the Agreement must be in writing and signed by all parties.

      NOW, THEREFORE, the parties agree as follows:

      1.          Schedule 1 of the Agreement shall be deleted in its entirety and replaced by Schedule 1 attached hereto.

      2.          Schedule 2 of the Agreement shall be deleted in its entirety and replaced by Schedule 2 attached hereto.

      3.          The effective date of this Amendment shall be July 1, 2020.  Except as specifically provided for in this Amendment, the terms of the Agreement are hereby ratified and confirmed and
        remain in full force and effect.

      

      

      4.          This Amendment, together with the Agreement and any other documents referred to herein, constitutes the whole agreement between the parties relating to the subject matter of this
        Amendment and supersedes and extinguishes any prior drafts, agreements, undertakings, representations, warranties and arrangements of any nature, whether in writing or oral, relating to such subject matter.

      

      

      5.          This Amendment may be executed in any number of counterparts, including via facsimile or email, each of which is an original and all of which when taken together evidence the same
        agreement. Any signature on the signature page of this Amendment may be an original, a fax or an electronically transmitted signature or may be executed by applying an electronic signature using DocuSign or, if permitted by the General Partner
        (such permission not to be unreasonably withheld), any other similar program.

      

      

      
        
          

      

      6.          This Amendment shall be governed by and construed in accordance with the laws of the State of New York.

      

      

      
        
          

      

      IN WITNESS WHEREOF, this Amendment has been executed for and on behalf of the undersigned as of the date first written above.

      

      	 	
              THE PARTNERSHIPS LISTED ON SCHEDULE 1 HERETO

               

            
	 	 	 
	 	 	 
	 	
              By: Ceres Managed Futures LLC

               

            
	 	 
	 	
              Name:

            	
              /s/ Patrick T. Egan

            
	 	 	
              Patrick T. Egan

            
	 	
              Title:

            	
              President

            
	 	 	 
	 	 	 
	 	
              Morgan Stanley Smith Barney LLC

               

            
	 	 
	 	
              Name:

            	
              /s/ Carmen Lai

            
	 	 	
              Carmen Lai

            
	 	
              Title:

            	
              Executive Director

            
	 	 	 
	 	 	 
	 	
              Ceres Managed Futures LLC

               

            
	 	 
	 	
              Name:

            	
              /s/ Patrick T. Egan

            
	 	 	
              Patrick T. Egan

            
	 	
              Title:

            	
              President

            
	 	 	 

      

      

      
        
          

      

      

      

      Schedule 1

      	
              PARTNERSHIP

            	
              STATE AND DATE OF ORGANIZATION

            	
              EFFECTIVE DATE

            
	
              Potomac Futures Fund L.P.

            	
              New York; March 14, 1997

            	
              October 1, 2013

            
	
              Ceres Abingdon L.P.

              (formerly Managed Futures Premier Abingdon L.P.)

            	
              New York; November 8, 2005

            	
              October 1, 2013

            
	
              Emerging CTA Portfolio L.P.

            	
              New York; July 7, 2003

            	
              October 1, 2013

            
	
              Ceres Tactical Commodity L.P.

              (formerly Managed Futures Premier Aventis II L.P.)

            	
              New York; April 20, 2005

            	
              October 1, 2013

            
	
              Ceres Tactical Systematic L.P. (formerly Tactical Diversified Futures Fund L.P.)

            	
              New York; December 3, 2002

            	
              October 1, 2013

            
	
              Ceres Orion L.P.

              (formerly Orion Futures Fund L.P.)

            	
              New York; March 22, 1999

            	
              March 1, 2014

            

      

      

    

    
      
        

    

    

      Schedule 2

      	
              PARTNERSHIP

               

            	
              ONGOING SELLING AGENT FEE

               

            
	
              Potomac Futures Fund L.P.

               

            	
              1.00% per year of the adjusted net assets of Class A Units (computed monthly by multiplying the adjusted net assets of the Class A Units by 1.00% and dividing the result thereof by 12).1  Class Z Units will not be subject to an ongoing selling agent fee.

            
	
              Ceres Abingdon L.P.

              (formerly Managed Futures Premier Abingdon L.P.)

            	
              1.00% per year of the adjusted net assets of Class A Units and 0.75% per year of the adjusted net assets of Class D Units (computed monthly by multiplying the adjusted net assets of the Class A Units by 1.00%
                and the adjusted net assets of the Class D Units by 0.75% and dividing the result thereof by 12).1  Class Z Units will not be subject to an ongoing selling agent fee.

            
	
              Emerging CTA Portfolio L.P.

               

            	
              1.00% per year of the adjusted net assets of Class A Units (computed monthly by multiplying the adjusted net assets of the Class A Units by 1.00% and dividing the result thereof by 12).1 Class Z
                Units will not be subject to an ongoing selling agent fee.

            
	
              Ceres Tactical Commodity L.P.

              (formerly Managed Futures Premier Aventis II L.P.)

            	
              1.00% per year of the adjusted net assets of Class A Units and 0.75% per year of the adjusted net assets of Class D Units (computed monthly by multiplying the adjusted net assets of the Class A Units by 1.00%
                and the adjusted net assets of the Class D Units by 0.75% and dividing the result thereof by 12).1  Class Z Units will not be subject to an ongoing selling agent fee.

            

      

      

      

        

        1           Adjusted net assets are month-end Net Assets increased by that current month’s ongoing selling agent fee,
          management fee, the general partner’s administrative fee, the incentive fee accrued, other expenses and any redemptions or distributions as of the end of such month.

      

      

      

      
        
          

      

      

      

      

      

      	
              Ceres Tactical Systematic L.P.

              (formerly Tactical Diversified Futures Fund L.P.)

            	
              1.00% per year of the adjusted net assets of Class A Units and 0.75% per year of the adjusted net assets of Class D Units (computed monthly by multiplying the adjusted net assets of the Class A Units by 1.00%
                and the adjusted net assets of the Class D Units by 0.75% and dividing the result thereof by 12).1  Class Z Units will not be subject to an ongoing selling agent fee.

            
	
              Ceres Orion L.P.

              (formerly Orion Futures Fund L.P.)

            	
              1.00% per year of the adjusted net assets of Class A Units (computed monthly by multiplying the adjusted net assets of the Class A Units by 1.00% and dividing the result thereof by 12).1  Class Z
                Units will not be subject to an ongoing selling agent fee.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]